secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001140361-26-011569
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics refutes Culper Research short seller allegations; provides inventory & demand data
--------------------------------------------------------------------------------

- Demand for ASCENIV growing; end-user demand increased past two years; current days on hand average 90 days as of March 22, 2026.
- Refutes channel stuffing; says distributor inventory levels consistent with industry standards; average days on hand above safety stock: 48 days for ASCENIV, 51 days for BIVIGAM as of March 22.
- ASCENIV positioned as late-line therapy for immune compromised patients who fail standard IG; premium pricing; new IVIG launches not competitive threat.
- ADMA received unqualified audit opinions from Big Four firm for FY2024 and FY2025; prior auditor resigned due to acquisition.
- No undisclosed related party transactions; no Grossman-family entity distributed or took title to any ADMA products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126011569/0001140361-26-011569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126011569/ef20069109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-011569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer